» Articles » PMID: 21148721

A Central Role for CD68(+) Macrophages in Hepatopulmonary Syndrome. Reversal by Macrophage Depletion

Abstract

Rationale: The etiology of hepatopulmonary syndrome (HPS), a common complication of cirrhosis, is unknown. Inflammation and macrophage accumulation occur in HPS; however, their importance is unclear. Common bile duct ligation (CBDL) creates an accepted model of HPS, allowing us to investigate the cause of HPS.

Objectives: We hypothesized that macrophages are central to HPS and investigated the therapeutic potential of macrophage depletion.

Methods: Hemodynamics, alveolar-arterial gradient, vascular reactivity, and histology were assessed in CBDL versus sham rats (n = 21 per group). The effects of plasma on smooth muscle cell proliferation and endothelial tube formation were measured. Macrophage depletion was used to prevent (gadolinium) or regress (clodronate) HPS. CD68(+) macrophages and capillary density were measured in the lungs of patients with cirrhosis versus control patients (n = 10 per group).

Measurements And Main Results: CBDL increased cardiac output and alveolar-arterial gradient by causing capillary dilatation and arteriovenous malformations. Activated CD68(+)macrophages (nuclear factor-κB+) accumulated in HPS pulmonary arteries, drawn by elevated levels of plasma endotoxin and lung monocyte chemoattractant protein-1. These macrophages expressed inducible nitric oxide synthase, vascular endothelial growth factor, and platelet-derived growth factor. HPS plasma increased endothelial tube formation and pulmonary artery smooth muscle cell proliferation. Macrophage depletion prevented and reversed the histological and hemodynamic features of HPS. CBDL lungs demonstrated increased medial thickness and obstruction of small pulmonary arteries. Nitric oxide synthase inhibition unmasked exaggerated pulmonary vasoconstrictor responses in HPS. Patients with cirrhosis had increased pulmonary intravascular macrophage accumulation and capillary density.

Conclusions: HPS results from intravascular accumulation of CD68(+)macrophages. An occult proliferative vasculopathy may explain the occasional transition to portopulmonary hypertension. Macrophage depletion may have therapeutic potential in HPS.

Citing Articles

Recruitment of pulmonary intravascular macrophages in SARS-CoV-2 infected hamsters.

Rodrigues C, Aulakh G, Kroeker A, Kulkarni S, Lew J, Falzarano D Cell Tissue Res. 2025; .

PMID: 40014090 DOI: 10.1007/s00441-025-03958-2.


RPL39 Was Associated With Sex Differences in Pulmonary Arterial Hypertension.

Wang H, Li L, Zhou G, Wang L, Wu Z Can Respir J. 2025; 2025:7139235.

PMID: 39957991 PMC: 11824382. DOI: 10.1155/carj/7139235.


Gut Microbiome and Pulmonary Arterial Hypertension - A Novel and Evolving Paradigm.

Thenappan T, Weir E Physiol Res. 2024; 73(S2):S477-S485.

PMID: 39589297 PMC: 11627261.


Immunoregulatory Macrophages Modify Local Pulmonary Immunity and Ameliorate Hypoxic Pulmonary Hypertension.

Fernandez-Gonzalez A, Mukhia A, Nadkarni J, Willis G, Reis M, Zhumka K Arterioscler Thromb Vasc Biol. 2024; 44(12):e288-e303.

PMID: 39387119 PMC: 11697987. DOI: 10.1161/ATVBAHA.124.321264.


Extrapulmonary manifestations of pulmonary arterial hypertension.

Singh N, Al-Naamani N, Brown M, Long G, Thenappan T, Umar S Expert Rev Respir Med. 2024; 18(3-4):189-205.

PMID: 38801029 PMC: 11713041. DOI: 10.1080/17476348.2024.2361037.


References
1.
Thenappan T, Goel A, Marsboom G, Fang Y, Toth P, Zhang H . A central role for CD68(+) macrophages in hepatopulmonary syndrome. Reversal by macrophage depletion. Am J Respir Crit Care Med. 2010; 183(8):1080-91. PMC: 3086745. DOI: 10.1164/rccm.201008-1303OC. View

2.
Hampl V, Bibova J, Banasova A, Uhlik J, Mikova D, Hnilickova O . Pulmonary vascular iNOS induction participates in the onset of chronic hypoxic pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol. 2005; 290(1):L11-20. DOI: 10.1152/ajplung.00023.2005. View

3.
Chang S, Ohara N . Pulmonary intravascular phagocytosis in liver disease. Clin Chest Med. 1996; 17(1):137-50. DOI: 10.1016/s0272-5231(05)70304-x. View

4.
Rodriguez-Roisin R, Krowka M, Herve P, Fallon M . Pulmonary-Hepatic vascular Disorders (PHD). Eur Respir J. 2004; 24(5):861-80. DOI: 10.1183/09031936.04.00010904. View

5.
Hampl V, Tristani-Firouzi M, Nelson D, Archer S . Chronic infusion of nitric oxide in experimental pulmonary hypertension: pulmonary pressure-flow analysis. Eur Respir J. 1996; 9(7):1475-81. DOI: 10.1183/09031936.96.09071475. View